Clinical observation of salvianolic acid B in treatment of liver fibrosis in chronic hepatitis B

Table 10 Correlation between change of fibrotic stages before and after treatment, liver function and serum fibrotic markers before treatment in SA-B group

Items	Improved (n = 11)	Unchanged (n = 13)	Deteriorated (n = 6)
Albumin (g/L)	40 ± 4.4	39.3 ± 6.5	39.5 ± 3.0
Globulin (g/L)	31.1 ± 6.7	33.9 ± 6.9	30.9 ± 8.5
ALT (U)	64 ± 41a	108 ± 83	201 ± 155
AST (U)	48 ± 29b	73 ± 55a	155 ± 108
GGT (U)	72 ± 44	99 ± 47	96 ± 54
Total bilirubin (mmol)	14.9 ± 3.9b	15.0 ± 6.6a	21 ± 10
Direct bilirubin (mmol)	2.9 ± 1.7	3.1 ± 2.3	5.0 ± 4.0
HA (μg/L)	172 ± 110	292 ± 188	386 ± 330
LN (μg/L)	106 ± 10	107 ± 21	91 ± 18
IV-C (μg/L)	248 ± 88	352 ± 176	284 ± 164
PIIIP (μg/L)	10.2 ± 6.8	14.8 ± 7.3	15 ± 10.2

Compared with elevation of stages,

^aP < 0.05,

^bP < 0.01